Russell Investments Group Ltd. grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 28.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,120 shares of the biopharmaceutical company’s stock after acquiring an additional 8,936 shares during the quarter. Russell Investments Group Ltd. owned about 0.09% of Ultragenyx Pharmaceutical worth $2,137,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 7.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares during the period. Tocqueville Asset Management L.P. raised its position in shares of Ultragenyx Pharmaceutical by 8.0% during the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 250 shares during the last quarter. Aperio Group LLC raised its position in shares of Ultragenyx Pharmaceutical by 8.4% during the second quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 299 shares during the last quarter. Amalgamated Bank raised its position in shares of Ultragenyx Pharmaceutical by 7.6% during the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 352 shares during the last quarter. Finally, Pacer Advisors Inc. raised its position in shares of Ultragenyx Pharmaceutical by 12.0% during the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 365 shares during the last quarter. 94.10% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Inc. (RARE) opened at $48.03 on Friday. The company has a market cap of $2,042.57, a price-to-earnings ratio of -6.89 and a beta of 1.84. Ultragenyx Pharmaceutical Inc. has a one year low of $43.14 and a one year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the consensus estimate of ($1.87). The firm had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.02 million. The firm’s quarterly revenue was up 81.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.64) earnings per share. analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.27 EPS for the current fiscal year.

Several equities research analysts have recently issued reports on RARE shares. Barclays started coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 6th. They set an “equal weight” rating and a $60.00 price objective on the stock. Canaccord Genuity reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 12th. Wedbush upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $62.00 price objective on the stock in a research report on Thursday, September 14th. Robert W. Baird reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 19th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $71.00 target price (up from $69.00) on shares of Ultragenyx Pharmaceutical in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. Ultragenyx Pharmaceutical has a consensus rating of “Hold” and an average price target of $72.40.

TRADEMARK VIOLATION WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/12/23/ultragenyx-pharmaceutical-inc-rare-position-increased-by-russell-investments-group-ltd.html.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.